Loading...
TNXP TONIX PHARMACEUTICALS HOLDING CORP Company Mergers 8-K Filing
Back
TNX
TNXP
TONIX PHARMACEUTICALS HOLDING CORP
(TNXP)
Follow
FY2023 8 K
View More
Back
TNX
TNXP
TONIX PHARMACEUTICALS HOLDING CORP
(TNXP)
Follow
FY2023 8 K
Filing:
8 K
Published on:
2 Feb '23
Reverse Stock Split
8 May '25
Product Expansion
29 Apr '25
Financial Statements
25 Apr '25
Product Expansion
24 Apr '25
Research Collaboration
9 Apr '25
Product Launch
1 Apr '25
FDA Update
24 Mar '25
Earnings Report
18 Mar '25
Grant Award
10 Mar '25
Management Change
4 Mar '25
Conference Presentation
4 Mar '25
NASDAQ Compliance
21 Feb '25
Financial Update
7 Feb '25
Positive Trial Results
6 Feb '25
Management Change
4 Feb '25
Loan Termination & Split
3 Feb '25
Management Change
8 Jan '25
FDA Approval Date
23 Dec '24
Share Offering Increase
20 Dec '24
FDA Application Accepted
17 Dec '24
Management Changes
3 Dec '24
Leadership Expansion
3 Dec '24
Vaccine Data Release
13 Nov '24
Quarterly Results
12 Nov '24
Product Update
8 Nov '24
Research Partnership
4 Nov '24
Vaccine Presentation
1 Nov '24
Shareholder Meeting
30 Oct '24
Q3 2024 Results
28 Oct '24
Funding Announcement
17 Oct '24
FDA Application
16 Oct '24
AI Collaboration
8 Oct '24
Patent Issuance
27 Sep '24
Product Presentation
23 Sep '24
Patent Issued
19 Sep '24
Vaccine Alignment
16 Sep '24
Management Change
10 Sep '24
Vaccine Presentation
9 Sep '24
Share Repurchase
6 Sep '24
Share Offering Increase
30 Aug '24
Vaccine Collaboration
26 Aug '24
Clinical Trial Update
20 Aug '24
Quarterly Results
19 Aug '24
Trial Results
12 Aug '24
Results of Operations and F...
9 Aug '24
Sales Agreement
30 Jul '24
FDA Fast Track Designation ...
25 Jul '24
Decommissioning of Facility
24 Jul '24
Update
16 Jul '24
Agreement for Public Offering
10 Jul '24
FDA Meeting for Tonmya NDA
8 Jul '24
Agreement with Defense Thre...
1 Jul '24
8-K Filing
28 Jun '24
Compliance with NASDAQ List...
26 Jun '24
FDA Meeting for Tonmya Prod...
20 Jun '24
Amendment to Filing
14 Jun '24
Agreement for Public Offering
13 Jun '24
Update
10 Jun '24
Reverse Stock Split
6 Jun '24
Data Announcement
6 Jun '24
Data from Phase 3 RESILIENT...
3 Jun '24
Data Announcement
30 May '24
Workforce Reduction and Dec...
22 May '24
ASCP Annual Meeting Present...
22 May '24
Market Assessment Results
21 May '24
Earnings Reports
13 May '24
Earnings Report
1 Apr '24
Securities Purchase Agreement
29 Mar '24
FDA Designation for TNX-290...
25 Mar '24
Poster Presentation at ACS ...
21 Mar '24
Selection of Contract Manuf...
20 Mar '24
Quantitative Data
19 Mar '24
Additional Efficacy Data An...
11 Mar '24
Publication of Research Paper
7 Mar '24
Investment Support for Tonm...
6 Mar '24
Announcement of TNX-1500 Ph...
5 Mar '24
Product Trial Completion
28 Feb '24
Clinical Study Results
27 Feb '24
Shareholder Approval
15 Feb '24
Engagement of Rho for NDA s...
13 Feb '24
FDA Clearance for OASIS Trial
12 Feb '24
Research Findings on Long C...
31 Jan '24
FDA Acceptance of Trade Name
29 Jan '24
Amendment to Articles of In...
25 Jan '24
Workforce Reduction
19 Jan '24
Additional Data Announcement
8 Jan '24
Update & FDA Decision
2 Jan '24
Securities Purchase Agreement
21 Dec '23
Positive Clinical Trial Res...
20 Dec '23
Update
12 Dec '23
Loan Agreement
8 Dec '23
FDA Clearance for TNX-2900 ...
4 Dec '23
Enrollment in Phase 2 study...
13 Nov '23
Earnings Report
9 Nov '23
Clinical Trial with TNX-180...
2 Nov '23
Discontinuation of TNX-601 ...
31 Oct '23
Data from oral presentation...
30 Oct '23
Product Launch
26 Oct '23
Notice from Nasdaq
20 Oct '23
Presentation at World Vacci...
19 Oct '23
Product Launch
18 Oct '23
Update
16 Oct '23
Clinical Phase Completion
16 Oct '23
Patent Issued
4 Oct '23
Securities Purchase Agreement
29 Sep '23
Investment
27 Sep '23
Update of Investor Presenta...
25 Sep '23
Research Results Announcement
21 Sep '23
Data Announcement
18 Sep '23
Announcement
14 Sep '23
FDA Feedback on Vaccine Can...
21 Aug '23
Phase 1 Study Initiation
16 Aug '23
Earnings Reports
10 Aug '23
Regulation FD Disclosure
7 Aug '23
Clinical Study Completion
7 Aug '23
Phase 3 trial completion
1 Aug '23
Enrollment in Phase 2 Study
31 Jul '23
Securities Purchase Agreement
28 Jul '23
Filing
27 Jul '23
Prioritization of TNX-4300 ...
26 Jul '23
New Product Launches
24 Jul '23
Enrollment in Phase 2 study...
17 Jul '23
Asset Acquisitions
3 Jul '23
Regulation FD Disclosure
26 Jun '23
Asset Purchase Agreement
26 Jun '23
Product Launches
15 Jun '23
Update
13 Jun '23
Data Announcement
7 Jun '23
Data Presentation
5 Jun '23
Presentation Update
1 Jun '23
Announcement of Presentatio...
31 May '23
Compliance Regained
25 May '23
Poster Presentation at ASCP...
25 May '23
Discovery of Isomers and De...
23 May '23
Research Collaboration Agre...
22 May '23
Product Launch
17 May '23
Reverse Stock Split
9 May '23
Earnings Reports
8 May '23
Annual Meeting of Shareholders
5 May '23
FDA Clears IND Application ...
4 May '23
Update of Presentations
1 May '23
Research Results Presentation
19 Apr '23
Publication of Articles on ...
17 Apr '23
Clinical Trials Update
13 Apr '23
Presentation of Vaccine Dev...
6 Apr '23
Research Results Announcement
5 Apr '23
Nasdaq Compliance Notice
4 Apr '23
Product Launch
30 Mar '23
Presentation on TNX-2900 data
23 Mar '23
Presentation Update
20 Mar '23
Enrollment in Phase 2 UPLIF...
16 Mar '23
Regulation FD Disclosure
13 Mar '23
Financial Results
13 Mar '23
Preclinical Results of mTNX...
7 Mar '23
Presentation Update
27 Feb '23
Appointment of Director
23 Feb '23
License Agreement
13 Feb '23
Product Launch
9 Feb '23
Conference Presentation
7 Feb '23
Enrollment in Phase 2 PREVE...
6 Feb '23
Acquisition of Healion Bio,...
2 Feb '23
Research Agreement with Uni...
1 Feb '23
Data Presentation on Migrai...
31 Jan '23
Compliance Regained
30 Jan '23
Announcement of Antiviral S...
26 Jan '23
Financial Results
25 Jan '23
Publication of Paper on Scr...
24 Jan '23
Presentation at Biotech Sho...
10 Jan '23
Appointment of Dr. Zeil Ros...
4 Jan '23
External Links:
SEC
AI Assistant
Close
TONIX PHARMACEUTICALS HOLDING CORP
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.